AI ASSISTANT
Ask DrugCentral
Explore drug information in your own words.
Type a question in the search bar above to get started. Each question is answered independently.
Try a sample question
Select a question to fill the search bar, then submit it or edit it first.
AI can make mistakes. Verify answers against the original sources before relying on them.
oxandrolone 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| anabolic steroids | 2011 | 53-39-4 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
A synthetic hormone with anabolic and androgenic properties.
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
None
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| BDDCS (Biopharmaceutical Drug Disposition Classification System) | 2 | Hosey CM, Chan R, Benet LZ |
| BA (Bioavailability) | 97 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
| S (Water solubility) | 0.01 mg/mL | Bocci G, Oprea TI, Benet LZ |
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| kinase-safety-class | ACVR2B,AXL,BRAF,CAMK2D,CDK5,CDK9,EIF2AK3,ERBB2,GRK2,ITK,MAPK7,NTRK2,PDK1,PDK2,PDK4,PRKDC,TEK | 17 | |||
| kinase-selectivity-class | EIF2AK3 | 1 | |||
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| July 21, 1964 | FDA | CREALTA PHARMS LLC |
FDA Adverse Event Reporting System (Female)
None
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Testicular atrophy | 69.10 | 42.66 | 9 | 403 | 407 | 110588480 |
| Polycythaemia | 64.01 | 42.66 | 11 | 401 | 3264 | 110585623 |
| Cardiac death | 63.80 | 42.66 | 10 | 402 | 1686 | 110587201 |
| Muscle mass | 59.28 | 42.66 | 8 | 404 | 475 | 110588412 |
| Drug abuse | 56.34 | 42.66 | 22 | 390 | 177389 | 110411498 |
| Left ventricular hypertrophy | 43.29 | 42.66 | 10 | 402 | 13234 | 110575653 |
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | A14AA08 | ALIMENTARY TRACT AND METABOLISM ANABOLIC AGENTS FOR SYSTEMIC USE ANABOLIC STEROIDS Androstan derivatives |
| MeSH PA | D000728 | Androgens |
| MeSH PA | D006728 | Hormones |
| MeSH PA | D045930 | Anabolic Agents |
| CHEBI has role | CHEBI:35610 | antineoplastic agent |
| CHEBI has role | CHEBI:36413 | anabolic agent |
| CHEBI has role | CHEBI:49201 | anti-ulcer drug |
| CHEBI has role | CHEBI:50113 | androgen |
| CHEBI has role | CHEBI:73336 | vulnerary |
| CHEBI has role | CHEBI:75835 | anti-anaemic agent |
Related Drugs by ATC class:
A14AA Androstan derivatives 8 drugs
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Catabolic Process | indication | ||
| Turner syndrome | off-label use | 38804009 | DOID:3491 |
| Hypercholesterolemia | contraindication | 13644009 | |
| Nephrotic syndrome | contraindication | 52254009 | DOID:1184 |
| Peliosis hepatis | contraindication | 58008004 | DOID:914 |
| Blood coagulation disorder | contraindication | 64779008 | DOID:1247 |
| Hypercalcemia | contraindication | 66931009 | DOID:12678 |
| Arteriosclerotic vascular disease | contraindication | 72092001 | |
| Heart failure | contraindication | 84114007 | DOID:6000 |
| Kidney disease | contraindication | 90708001 | DOID:557 |
| Cholestatic hepatitis | contraindication | 95556007 | |
| Neoplasm of liver | contraindication | 126851005 | DOID:3571 |
| Neoplasm of prostate | contraindication | 126906006 | DOID:10283 |
| Hypoalphalipoproteinemia | contraindication | 190785000 | |
| Disease of liver | contraindication | 235856003 | DOID:409 |
| Benign prostatic hyperplasia | contraindication | 266569009 | |
| Edema | contraindication | 267038008 | |
| Pregnancy, function | contraindication | 289908002 | |
| Breastfeeding (mother) | contraindication | 413712001 | |
| Disorder of coronary artery | contraindication | 414024009 | |
| Breast Carcinoma in Males | contraindication |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
None
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Androgen receptor | Nuclear hormone receptor | AGONIST | IC50 | 9.09 | CHEMBL | CHEMBL |
External reference:
| ID | Source |
|---|---|
| 4018126 | VUID |
| N0000146464 | NUI |
| D00462 | KEGG_DRUG |
| 4018126 | VANDF |
| C0029995 | UMLSCUI |
| CHEBI:7820 | CHEBI |
| CHEMBL1200436 | ChEMBL_ID |
| DB00621 | DRUGBANK_ID |
| D010074 | MESH_DESCRIPTOR_UI |
| 5878 | PUBCHEM_CID |
| 7092 | IUPHAR_LIGAND_ID |
| 1325 | INN_ID |
| 7H6TM3CT4L | UNII |
| 224933 | RXNORM |
| 4491 | MMSL |
| 5209 | MMSL |
| 91416 | MMSL |
| d00566 | MMSL |
| 001258 | NDDF |
| 126128007 | SNOMEDCT_US |
| 2679000 | SNOMEDCT_US |
| 7H6TM3CT4L | INXIGHT DRUGS |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| Oxandrolone | HUMAN PRESCRIPTION DRUG LABEL | 1 | 49884-301 | TABLET | 2.50 mg | ORAL | ANDA | 20 sections |
| Oxandrolone | HUMAN PRESCRIPTION DRUG LABEL | 1 | 49884-302 | TABLET | 10 mg | ORAL | ANDA | 20 sections |